Blueberries Medical Appoints Former Clever Leaves Global Head of B2B as President of Latin American Operations
Blueberries Medical Corp. (CSE: BBM, OTC: BBRRF) has appointed José María Forero as President of Latin American Operations, effective February 16, 2021. Forero, with over 17 years of experience, previously served as Global Head of B2B at Clever Leaves. His expertise in sales and international operations aims to enhance Blueberries' global growth strategy. The company is well-positioned to meet rising demand with its advanced extraction facility and cultivation capacity in Colombia and Argentina. Blueberries is committed to becoming a key player in the international cannabis market.
- José María Forero brings 17+ years of experience, which may enhance operational efficiency.
- Strategic leadership change may strengthen Blueberries' position for global growth.
- The company has established a state-of-the-art extraction facility, poised to ramp up production.
- Transition to a new president may create temporary disruption in operations.
- Uncertainty in the cannabis market may affect the company's growth trajectory.
TORONTO, Feb. 10, 2021 (GLOBE NEWSWIRE) -- Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the “Company” or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to announce the appointment of José María Forero, the former Global Head of B2B of Clever Leaves Holdings Inc. (NASDAQ: CLVR) (“Clever Leaves”) as President of Latin American Operations, effective February 16, 2021.
Mr. Forero is a C-level executive with 17+ years of regional and global experience in sales having led successful development of commercial departments within numerous companies, including most recently Clever Leaves, the largest medical cannabis licensed producer in Colombia. Mr. Forero is an Industrial Engineer and has an Executive MBA degree from INALDE Busines School.
Mr. Forero has extensive knowledge of and relationships within the global cannabis industry and will utilize his operational and sales expertise to guide the next phase of the company’s international development and growth, working together with Facundo Garreton, Chairman and Interim CEO of Blueberries.
Mr. Garreton commented: “We are pleased to welcome Mr. Forero to our team. We are confident that with the addition of Mr. Forero, our Latin American operations are well equipped for global growth and success.”
"Blueberries has made impressive progress in a relatively short period of time developing their cultivation and extraction infrastructure," stated Mr. Forero. "With Blueberries’ state of the art extraction facility and commercial cultivation capacity established, it is well positioned to ramp up production and meet local and international demand. I am looking forward to guiding Blueberries local team in this process as well as establishing a solid operation capable of adapting to the global market conditions."
About Blueberries Medical Corp.
Blueberries is a Latin American licensed producer of naturally grown premium quality cannabis with its primary operations ideally located in the Bogotá Savannah of central Colombia and operations currently being established in Argentina. The Company is led by a specialized team with proprietary expertise in agriculture, genetics, extraction, medicine, pharmacology and marketing, Blueberries is fully licensed for the cultivation, production, domestic distribution, and international export of CBD and THC-based medical cannabis in Colombia. Blueberries’ combination of leading scientific expertise, agricultural advantages and distribution arrangements has positioned the Company to become a leading international supplier of naturally grown, processed, and standardized medicinal-grade cannabis oil extracts and related products.
Additional information about the Company is available at www.blueberriesmed.com. For more information, please contact:
Facundo Garretón, Chairman and Interim Chief Executive Officer
E: fgarreton@gmail.com
Ian Atacan, Chief Financial Officer
E: iatacan@blueberriesmed.com
Tel: +1 (416) 562 3220
Cautionary Note Regarding Forward-Looking Information
This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward looking statements relate, among other things, to: commencement of commercial production of CBD-dominant oils and products, successful implementation of full GMP standards at its extraction facility to allow for additional export potential to international markets, achieving additional milestones is contemplated, or at all, ability to expand distribution networks, ability to expand and upgrade the Company’s cultivation facilities in Colombia, internal expectations, expectations regarding the ability of the Company to access new Latin American and international markets, the ability to attract and retain new customers, and future expansion plans including development of the cultivation, production, industrialization and marketing of cannabis for commercial and scientific purposes.
These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the Colombian and international medical cannabis market and changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution and sale of cannabis and cannabis related products in Colombia, Argentina and elsewhere; and employee relations. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.
Additional information regarding the Company, and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's Listing Statement dated January 31, 2019 filed on its issuer profile on SEDAR at www.sedar.com.
No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
FAQ
Who is José María Forero and what will be his role at Blueberries Medical Corp.?
What impact might José María Forero's appointment have on Blueberries Medical Corp.?
What are Blueberries Medical Corp.'s main operations?
Is Blueberries Medical Corp. positioned for market expansion?
